Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

NCT06937905 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

129

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Carcinoma

Interventions

DRUG: Standard of Care Chemotherapy
DRUG: Tarlatamab

Sponsor

Intergroupe Francophone de Cancerologie Thoracique